Biotinylated Human CD96/TACTILE Protein
Catalog No: CD96-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD96/TACTILE Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Val22-Met503 (UniProt accession: P40200-2).
Product Details
- Molecular Aliases
- CD96 molecule; CD96; DKFZp667E2122; TACTILE
- Protein Length
- Val22-Met503
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 59.1 kDa. Due to glycosylation, the protein migrates to 90-140 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CD96 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Biotinylated Human CD96, His-Avi tag at 2μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-CD96 Antibody, hFc Tag with the EC50 of 19.8ng/ml determined by ELISA.
Background
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
References
- Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432. CCR-16-0933. Epub 2016 Sep 12. PMID: 27620276.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.